Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD19 chimeric antigen receptor T cell therapy - AbelZeta Pharma

Next Previous
X
Search
Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - AbelZeta Pharma

Alternative Names: Anti-CD19 CART cell therapy - AbelZeta Pharma ; Anti-CD19 CART cells; C-CAR011; CD19 specific CART cells

Latest Information Update: 27 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer AbelZeta Pharma; Chinese PLA General Hospital
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma; Follicular lymphoma; Leukaemia; Mantle-cell lymphoma
  • No development reported Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
  • 02 May 2023 Cellular Biomedicine's CAR T assets licensed to Janssen Biotech worldwide except for Greater China for B-cell malignancies
  • 28 Jun 2022 No recent reports of development identified for phase-I development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Second-line therapy or greater) in China (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top